BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10746802)

  • 1. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; van Kuijk FJ; Ehrich JH; Siems WG
    Nephrol Dial Transplant; 1998 Oct; 13(10):2583-7. PubMed ID: 9794564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment.
    Siems W; Carluccio F; Radenkovic S; Grune T; Hampl H
    Kidney Blood Press Res; 2005; 28(5-6):295-301. PubMed ID: 16534224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
    Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
    Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients.
    Usberti M; Gerardi G; Micheli A; Tira P; Bufano G; Gaggia P; Movilli E; Cancarini GC; De Marinis S; D'Avolio G; Broccoli R; Manganoni A; Albertin A; Di Lorenzo D
    J Nephrol; 2002; 15(5):558-64. PubMed ID: 12455724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress markers and C-reactive protein in pediatric patients on hemodialysis.
    Elshamaa MF; Sabry S; Nabih M; Elghoroury EA; El-Saaid GS; Ismail AA
    Ann Nutr Metab; 2009; 55(4):309-16. PubMed ID: 19828941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid and alpha-keto acid metabolism depends on oxygen availability in chronic hemodialysis patients.
    Riedel E; Nündel M; Wendel G; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S56-60. PubMed ID: 10746807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments.
    Lucchi L; Bergamini S; Iannone A; Perrone S; Stipo L; Olmeda F; Caruso F; Tomasi A; Albertazzi A
    Artif Organs; 2005 Jan; 29(1):67-72. PubMed ID: 15644086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete correction of renal anemia by recombinant human erythropoietin.
    Ludat K; Paulitschke M; Riedel E; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.